Company profile
JASPER THERAPEUTICS, INC.
NASDAQ:JSPRBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| BRIQUILIMAB | phase2 | — | 5 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06353971 | phase1_2 | terminated | 2024-03-18 | 2025-07-31 | Jasper Therapeutics, Inc. | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines |
| NCT06592768 | phase1 | terminated | 2024-11-26 | 2025-08-11 | Jasper Therapeutics, Inc. | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma |
| NCT06736262 | phase2 | terminated | 2024-11-26 | 2026-07-21 | Jasper Therapeutics, Inc. | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials |
| NCT06162728 | phase1_2 | completed | 2023-11-29 | 2026-07-08 | Jasper Therapeutics, Inc. | Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU) |
| NCT05903274 | phase1 | terminated | 2023-06-19 | 2024-10-21 | Jasper Therapeutics, Inc. | JSP191 (briquilimab) in Subjects with LR-MDS |
FDA applications (0)
No records yet.